Portfolio
Bolden Therapeutics
Bolden Therapeutics is developing first-in-class therapeutics to increase neurogenesis and improve outcomes in neurological disease.
Deciduous Therapeutics
Deciduous Therapeutics is developing novel immunotherapies that activate the body's immune system to target and eliminate pathogenic senescent cells, offering promising treatments for age-related diseases and overall improvements in health-span.
EpiBone
EpiBone, Inc. is a privately held clinical-stage regenerative medicine company focused on
skeletal reconstruction.
Fauna Bio
Fauna Bio is a first-of-its-kind biotech company that studies the protective genotypes across extreme biology to develop new therapies to improve human health
and lifespan.
General Proximity
The next generation of induced proximity medicines.
LIfT Biosciences
LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil-based immunotherapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly.
Marble Therapeutic
Marble Therapeutics is a biotechnology company with an overarching goal to pioneer real-world rejuvenation and enhancement products through a first-in-kind causal inference understanding of nonlinear dynamics in biology.
Matter Bio
Matter Bio is a longevity holding company focused on quantifying and reversing DNA damage to prevent diseases of aging and increase healthy lifespan.
Modulo Bio
Modulo is a platform driven biotech startup focused on developing therapies that reprogram the brain’s immune system to slow or reverse neurological diseases.
NaNotics
NaNotics is a biopharmaceutical company developing NaNots™, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood.
Rejuvenate Bio
Rejuvenate Bio is a spinout from the Wyss Institute at Harvard focused on reversing aging and eliminating age-related disease. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to patients suffering from age-related conditions.
Rejuvenation Technologies
Rejuvenation Technologies is developing mRNA therapies to treat aging biology and related diseases. The company uses lipid nanoparticles to deliver telomerase mRNA to restore telomere length and tissue regenerative capacity.
SENISCA
SENISCA has identified a new, druggable molecular cause of cellular ageing (senescence): RNA splicing dysregulation. The Company is developing oligonucleotide senotherapeutics that target splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.